ADVERTISEMENT
ADVERTISEMENT
If you are not happy with the results below please do another search
WuXi Biologics has agreed to sell its Dundalk vaccine manufacturing facility to Merck, a move that will enhance asset efficiencies and allow the company to focus on CDMO services at its other global sites.
Immuncheckpoint specialist Oxford BioTherapeutics has licenced the right to develop five bispecific antibodies for combination therapies using Wuxi Biologics WuXiBody platform.
The BIOSECURE Act of the United States could affect more than 120 US biopharmaceutical drugs partnered with Chinese companies ‘of concern’, as named in the bill. Of these, approximately half are in clinical trials (phases I to III) and a third are in early preclinical and discovery stages, according to GlobalData, the analytics company.